jueves, 23 de junio de 2016
Cancer Currents Blog: Extended Adjuvant Therapy Beneficial for Some Women with Breast
Extended Adjuvant Therapy for Breast Cancer - National Cancer Institute
Results from a recent clinical trial showed that extending adjuvant therapy with an aromatase inhibitor to 10 years after initial treatment can have important benefits for postmenopausal women with early-stage hormone receptor (HR)–positive breast cancer. The longer treatment improved 5-year disease-free survival and decreased the women’s risk of developing cancer in the opposite breast, called contralateral breast cancer. The findings were published in the New England Journal of Medicine on June 5 and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.